Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
European Myeloma Network B.V.
Nantes University Hospital
Wake Forest University Health Sciences
Pfizer
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Roswell Park Cancer Institute
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
University of Chicago
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Trials Ireland
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Pfizer
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Weill Medical College of Cornell University
Janssen Research & Development, LLC
University Hospital, Lille
Alexion Pharmaceuticals, Inc.
Hangzhou Sumgen Biotech Co., Ltd.
National Cancer Institute (NCI)